RYKINDO

Peak

risperidone

Luye Pharma
NDAINTRAMUSCULARFOR SUSPENSION, EXTENDED RELEASE
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Clinical Trials (5)

NCT04418466Phase 1/2Completed

Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

Started Apr 2021
NCT03978832Phase 4Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Started Jun 2019
69 enrolled
Schizophrenia
NCT03713658Phase 4Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Started Oct 2018
34 enrolled
Schizophrenia
NCT03390712N/AUnknown

Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection

Started Jan 2018
328 enrolled
Schizophrenia Spectrum and Other Psychotic Disorders
NCT02758067Phase 3Withdrawn

Comparison of the Effectiveness of Brexpiprazole With That of Risperidone

Started Jun 2016
0
Schizophrenia

Loss of Exclusivity

LOE Date
Apr 10, 2032
74 months away
Patent Expiry
Apr 10, 2032

Patent Records (5)

Patent #ExpiryTypeUse Code
10098882
Apr 10, 2032
Product
U-3513
10406161
Apr 10, 2032
Product
U-3513
11110094
Apr 10, 2032
Product
—
9446135
Apr 10, 2032
Product
U-3513
9532991
Apr 10, 2032
Product
U-3513
Company
Luye Pharma
Luye Pharma
China - Shanghai
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers